Guggenheim analyst Michael Schmidt upgraded Incyte (INCY) to Buy from Neutral with a $125 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Knight Therapeutics announces approval, launch of MINJUVI in Argentina
- Incyte price target raised to $93 from $79 at Truist
- Incyte price target raised to $84 from $81 at RBC Capital
- Incyte price target raised to $109 from $104 at BofA
- Incyte’s Strong Financial Performance and Strategic Catalysts Drive Buy Rating